Prognostic Factors in Real World Patients Receiving Durvalumab After Chemo-Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (LA NSCLC) – The Experience of Oncology Institute “Prof. Dr. Ion Chiricuta”

Purpose and methods: We aimed to evaluate in rw pts, the safety profile, effectiveness and prog-nostic factors associated with the RR, PFS, and secondarily, OS of durvalumab, after c/sCRT, without progression, in LA NSCLC, PD-L1 ≥ 1%. Durvalumab was administered 10 mg/kg at 2 weeks or monthly 1500 mg iv, until disease progression or unacceptable toxicity, no more than a year. Results: Eligible were 75 pts with LA NSCLC, PD-L1 ≥ 1%, but 10 (13.3%) progressed after CRT, thus evaluated were 65 pts. Discontinuation of durvalumab occurred in 23% due to grade ≥ 3 adverse events and in 23% for disease progression. DC in 60% was associated significantly by PS, NC, NLR and AS only approached the significance level. PFS of 30% at 2 years, with a median value of 18 months, was significantly associated with age, PS, NC, NLR, AS. In the multivariable analysis significant prognostic factor remained PS and AS approached significance level. OS of 55% at 2 years and mOS was 26.1 months. Conclusions: Durvalumab after CRT in rw pts with LA NSCLC demonstrate a good safety profile, promising RR, PFS and OS, consistent with other rw analyses. Age, PS, AS, NC, NLR, were associated significantly with PFS. PS remained significant prognostic factors, in the multivariable analysis. AS only approached the significance level war-ranting further investigations concerning the role of psychological profile and support in LA NSCLC.

Authors

Publication Details

Journal
Preprints.org
Published
2026-11-18
DOI
https://doi.org/10.20944/preprints202611.1931.v1
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Prognostic Factors in Real World Patients Receiving Durvalumab After Chemo-Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (LA NSCLC) – The Experience of Oncology Institute “Prof. Dr. Ion Chiricuta”

Petronela Rusu, Tudor–Eliade Ciuleanu, Zsolt Fekete, Leonard Dominic Rusu et al.
Preprints.org
Cancer Immunotherapy and Biomarkers
preprint

Prognostic Factors in Real World Patients Receiving Durvalumab After Chemo-Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (LA NSCLC) – The Experience of Oncology Institute “Prof. Dr. Ion Chiricuta”

Petronela Rusu, Tudor–Eliade Ciuleanu, Zsolt Fekete, Leonard Dominic Rusu, Nicolae Todor, Renata Andrea Rusu-Patraulea, Irina Bondei, Claudia Burz
preprint en

Abstract

Purpose and methods: We aimed to evaluate in rw pts, the safety profile, effectiveness and prog-nostic factors associated with the RR, PFS, and secondarily, OS of durvalumab, after c/sCRT, without progression, in LA NSCLC, PD-L1 ≥ 1%. Durvalumab was administered 10 mg/kg at 2 weeks or monthly 1500 mg iv, until disease progression or unacceptable toxicity, no more than a year. Results: Eligible were 75 pts with LA NSCLC, PD-L1 ≥ 1%, but 10 (13.3%) progressed after CRT, thus evaluated were 65 pts. Discontinuation of durvalumab occurred in 23% due to grade ≥ 3 adverse events and in 23% for disease progression. DC in 60% was associated significantly by PS, NC, NLR and AS only approached the significance level. PFS of 30% at 2 years, with a median value of 18 months, was significantly associated with age, PS, NC, NLR, AS. In the multivariable analysis significant prognostic factor remained PS and AS approached significance level. OS of 55% at 2 years and mOS was 26.1 months. Conclusions: Durvalumab after CRT in rw pts with LA NSCLC demonstrate a good safety profile, promising RR, PFS and OS, consistent with other rw analyses. Age, PS, AS, NC, NLR, were associated significantly with PFS. PS remained significant prognostic factors, in the multivariable analysis. AS only approached the significance level war-ranting further investigations concerning the role of psychological profile and support in LA NSCLC.

Preprints.org
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon